The Distribution of Low and High-risk HPV Types in Vulvar and Vaginal Intraepithelial Neoplasia (VIN and VaIN)
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
It has been proposed that low-grade vulvar and vaginal lesions (VIN 1 and VaIN 1) are flat condylomas and should be designated as such. Moreover, their relationship to high-grade lesions (VIN 3 and VaIN 3) is unclear. Accordingly, this study was undertaken to address these issues by comparing the distribution of human papillomavirus (HPV) types in vulvar and vaginal intraepithelial lesions. We identified 33 cases of VIN 1, 34 cases of VIN 3, 17 cases of VaIN 1, and 16 cases of VaIN 3. In addition, 36 cases of low-grade squamous intraepithelial lesion (LSIL) in the cervix and 116 cases of cervical high-grade squamous intraepithelial lesion were used for comparison. Polymerase chain reaction analysis was performed using both the Roche PGMY and DDL SPF 10 systems. In cases where HPV was detected, the majority of low-grade and high-grade lesions contained a single HPV type. However, a minority of cases were found to have multiple HPV types. Of the VIN 1 cases, a low-risk virus was seen in 22 (67%), with HPV 6 or 11 accounting for 14 (42%). A high-risk virus was detected in 14 (42%) of cases of which 2 (6%) contained HPV 16. Of the VIN 3 cases, all had high-risk HPV of which 31 (91%) were found to have HPV 16. Of the VaIN 1 cases, 6 (35%) were found to have low-risk HPV types. HPV 6 or 11 were not found in these cases. High-risk virus was seen in 13 (76%) VaIN 1 cases, with 1 (6%) containing HPV 16. HPV was detected in 15 of 16 (94%) VaIN 3 lesions, all of which had high-risk types. HPV 16 was found in 8 (50%). In contrast, 2 (6%) of cervical LSIL had low-risk HPV (HPV 6 and 11), whereas 34 (94%) of LSIL cases had high-risk HPVs. Of the cervical high-grade squamous intraepithelial lesion cases, 100% had high-risk HPVs of which 87 (75%) were found to have HPV 16. The findings demonstrate that a significant number of low-grade vulvar and vaginal lesions contain high-risk HPV types, supporting their designation as low-grade intraepithelial lesions rather than flat condylomas. The low frequency of HPV 16 in VIN 1 compared with VIN 3 suggests they are distinct lesions or that HPV 16 is critical in the progression to VIN 3. Finally, comparison of the distribution of HPV in the vagina and vulva suggests that VaIN is more closely related to cervical intraepithelial neoplasia than to VIN.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiologic classification of human papillomavirus types associated with cervical cancer
Muñoz, N., Bosch, F. X., de Sanjosé, S., Herrero, R., Castellsagué, X., Shah, K. V., Snijders, P. J. F., & Meijer, C. J. L. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021641 · Cited by 6,249 · cited 2×
“Moreover, approximately 50% of high-grade cervical squamous intraepithelial lesions and invasive squamous carcinomas are associated with HPV 16.(2,3,9,10,12) In this study, 76% of VaIN 1 were associated with high-risk HPV and 50% of VaIN 3 contained HPV 16.”
BackgroundHuman papillomavirus and cervical cancer
Burd, E. M. (2003) · Clinical Microbiology Reviews · doi:10.1128/cmr.16.1.1-17.2003 · Cited by 2,420 · cited 2×
“Moreover, approximately 50% of high-grade cervical squamous intraepithelial lesions and invasive squamous carcinomas are associated with HPV 16.(2,3,9,10,12) In this study, 76% of VaIN 1 were associated with high-risk HPV and 50% of VaIN 3 contained HPV 16.”
BackgroundClifford, G. M., Smith, J. S., Aguado, T., & Franceschi, S. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601024 · Cited by 684 · cited 2×
“Moreover, approximately 50% of high-grade cervical squamous intraepithelial lesions and invasive squamous carcinomas are associated with HPV 16.(2,3,9,10,12) In this study, 76% of VaIN 1 were associated with high-risk HPV and 50% of VaIN 3 contained HPV 16.”
BackgroundPathogenesis of Human Papillomaviruses in Differentiating Epithelia
Longworth, M. S., & Laimins, L. A. (2004) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.68.2.362-372.2004 · Cited by 677 · cited 2×
“Moreover, approximately 50% of high-grade cervical squamous intraepithelial lesions and invasive squamous carcinomas are associated with HPV 16.(2,3,9,10,12) In this study, 76% of VaIN 1 were associated with high-risk HPV and 50% of VaIN 3 contained HPV 16.”
Background(ALTS) Group, T. A. S. C. O. U. S. /.-G. S. I. L. T. S. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.5.397 · Cited by 438
A Population-Based Study of Squamous Cell Vaginal Cancer: HPV and Cofactors
Daling, J. R., Madeleine, M. M., Schwartz, S. M., Shera, K. A., Carter, J. J., McKnight, B., Porter, P. L., Galloway, D. A., McDougall, J. K., & Tamimi, H. (2002) · Gynecologic Oncology · doi:10.1006/gyno.2001.6502 · Cited by 346
Sideri, M., Jones, R. W., Wilkinson, E. J., Preti, M., Heller, D. S., Scurry, J., Haefner, H., & Neill, S. (2006) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000201921.69949.10 · Cited by 339
Human papillomaviruses: targeting differentiating epithelial cells for malignant transformation
Fehrmann, F., & Laimins, L. A. (2003) · Oncogene · doi:10.1038/sj.onc.1206554 · Cited by 292 · cited 2×
“Moreover, approximately 50% of high-grade cervical squamous intraepithelial lesions and invasive squamous carcinomas are associated with HPV 16.(2,3,9,10,12) In this study, 76% of VaIN 1 were associated with high-risk HPV and 50% of VaIN 3 contained HPV 16.”
BackgroundCoutlée, F., Gravitt, P., Kornegay, J., Hankins, C., Richardson, H., Lapointe, N., Voyer, H., & Franco, E. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.3.902-907.2002 · Cited by 181 · cited 1×
“Kornegay of Roche Molecular Systems).(4) Initial strip typing negatives were rehybridized with double the amount of amplicons to improve sensitivity.”
BackgroundVulvar Squamous Cell Carcinoma in Young Women: A Clinicopathologic Study of 21 Cases
Al-Ghamdi, A., Freedman, D., Miller, D., Poh, C., Rosin, M., Zhang, L., & Gilks, C. B. (2002) · Gynecologic Oncology · doi:10.1006/gyno.2001.6466 · Cited by 158
van Doorn, L.-J., Quint, W., Kleter, B., Molijn, A., Colau, B., Martin, M.-T., Kravang-In, Torrez-Martinez, N., Peyton, C. L., & Wheeler, C. M. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.3.979-983.2002 · Cited by 127 · cited 2×
“450 bp for PGMY), which can be more efficiently produced out of paraffin-extracted DNA.(13,18) Amplification followed the Delft Diagnostic Laboratory (DDL) clinical typing protocol, with substitution of the ethidium bromide stained gels for the DDL assay to detect positive results.”
MethodQuint, W. G. V., Scholte, G., van Doorn, L. J., Kleter, B., Smits, P. H. M., & Lindeman, J. (2001) · The Journal of Pathology · doi:10.1002/path.855 · Cited by 92 · cited 2×
“450 bp for PGMY), which can be more efficiently produced out of paraffin-extracted DNA.(13,18) Amplification followed the Delft Diagnostic Laboratory (DDL) clinical typing protocol, with substitution of the ethidium bromide stained gels for the DDL assay to detect positive results.”
MethodPathobiology of vulvar squamous neoplasia
Crum, C. P., McLachlin, C. M., Tate, J. E., & Mutter, G. L. (1997) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/00001703-199702000-00014 · Cited by 81
The Impact of Human Papillomavirus Biology on the Clinical Practice of Cervical Pathology
Stoler, M. H. (2005) · Pathology Case Reviews · doi:10.1097/01.pcr.0000161169.34009.6c · Cited by 7
Self-citation
Cited by
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women
Joura, E. A., Giuliano, A. R., Iversen, O.-E., Bouchard, C., Mao, C., Mehlsen, J., Moreira, E. D., Ngan, Y., Petersen, L. K., Lazcano-Ponce, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1405044 · Cited by 1,433
Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia
Kenter, G. G., Welters, M. J. P., Valentijn, A. R. P. M., Lowik, M. J. G., Berends-van der Meer, D. M. A., Vloon, A. P. G., Essahsah, F., Fathers, L. M., Offringa, R., Drijfhout, J. W., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810097 · Cited by 1,102
Brown, D. R., Kjaer, S. K., Sigurdsson, K., Iversen, O., Hernandez‐Avila, M., Wheeler, C. M., Perez, G., Koutsky, L. A., Tay, E. H., Garcia, P., et al. (2009) · The Journal of Infectious Diseases · doi:10.1086/597307 · Cited by 627
Self-citationDougan, M., & Dranoff, G. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132544 · Cited by 607
Joura, E. A., Leodolter, S., Hernandez-Avila, M., Wheeler, C. M., Perez, G., Koutsky, L. A., Garland, S. M., Harper, D. M., Tang, G. W., Ferris, D. G., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60777-6 · Cited by 581
Metadata
- Authors
- Srodon, M., Stoler, M. H., Baber, G. B., & Kurman, R. J.
- Venue
- American Journal of Surgical Pathology
- Published
- 2006-12
- Volume
- 30
- Issue
- 12
- Pages
- 1513-1518
- ISSN
- 0147-5185 (ISSN-L)
- OpenAlex
- W2086373192
- Cited by
- 213
- References
- 14
- FWCI
- 11.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.